Amneal Pharmaceuticals, Inc. (AMRX) News
Filter AMRX News Items
AMRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AMRX News Highlights
- AMRX's 30 day story count now stands at 3.
- Over the past 14 days, the trend for AMRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest AMRX News From Around the Web
Below are the latest news stories about AMNEAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMRX as an investment opportunity.
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceBRIDGEWATER, N.J., December 21, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. Chirag will present on January 10th at 11:15 AM PST, and a live webcast will be accessible on the Company's website at https://investors.amneal.com. A replay of the webcast will be available for 30 days f |
Amneal Announces Move to NasdaqBRIDGEWATER, N.J., December 15, 2023--Amneal Pharmaceuticals, Inc. ("Amneal") (NYSE: AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market ("Nasdaq") from the New York Stock Exchange ("NYSE"). The Company expects the Nasdaq listing to occur on December 27, 2023 and will continue to trade under the current symbol "AMRX". Upon transferring, Amneal will become part of the Nasdaq Composite Index and Nasdaq Biotechnology Index. |
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)BRIDGEWATER, N.J. & PORTO, Portugal, December 07, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal") and BIAL - Portela & Ca., S.A. ("BIAL"), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023. Amneal expects to begin distribution of ONGENTYS® in early 2024. |
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel CapsulesBRIDGEWATER, N.J., December 01, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") and Strides Pharma Science Limited ("Strides") today announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®. The product has been in-licensed from Strides, a global pharmaceutical manufacturer, and will be commercialized by Amneal starting in the fourth quarter of 2023. |
Should You Be Excited About Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) 20% Return On Equity?One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will... |
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year. |
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2023 Earnings Call TranscriptAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2023 Earnings Call Transcript November 7, 2023 Amneal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.19, expectations were $0.12. Operator: Good morning, and welcome to the Amneal Third Quarter 2013 Earnings Call. I will now turn the call over to Amneal Head of Investor Relations, Anthony DiMeo. Anthony DiMeo: […] |
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
Amneal Pharmaceuticals Inc (AMRX) Reports 14% Increase in Q3 2023 Net RevenueAdjusted EBITDA Grows by 22% Year-Over-Year |
Amneal Reports Third Quarter 2023 Financial ResultsBRIDGEWATER, N.J., November 07, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") announced its results today for the third quarter ended September 30, 2023. |